PLpro Inhibitor Compounds for Viral Repression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PLpro inhibitors for viral infections, such as those caused by coronaviruses, have limitations in therapeutic profile and activity, necessitating the development of new compounds with improved efficacy.
Innovation Solution
The development of novel compounds of Formula (I) and their pharmaceutically acceptable salts, which inhibit papain-like protease (PLpro) activity, potentially used in treating viral infections by combining with other therapeutic agents to enhance clinical benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PLpro inhibitors are used, then viral replication can be suppressed, but the therapeutic profile and activity are insufficient
Solution Approach 1:
The patent modifies the chemical structure of existing PLpro inhibitors by changing parameters such as substituting hydrogen atoms with fluorine atoms, adding methyl groups, or introducing different heterocyclic rings at specific positions (R1-R17 groups). These parameter changes in the molecular structure aim to improve both the therapeutic profile and antiviral activity simultaneously.
Solution Approach 2:
The invention creates composite molecular structures by combining different functional groups and heterocyclic systems (e.g., pyridine, pyrimidine, triazine rings combined with various substituent groups). These composite structures are designed to achieve superior therapeutic profiles and enhanced viral replication suppression compared to single-component inhibitors.
2Productivity
If PLpro enzymatic activity is inhibited, then viral replication is prevented, but host immune response modulation is affected
Solution Approach 1:
The patent introduces specific substituent groups at localized positions (R1-R17) on the inhibitor molecule that differentially interact with the PLpro enzyme. Certain substituents are designed to enhance viral replication suppression while others are optimized to minimize interference with host immune response pathways, achieving selective inhibition.
Solution Approach 2:
The invention develops a series of inhibitor analogs with varying stability profiles, where certain compounds are designed for potent but transient inhibition to suppress viral replication acutely, while avoiding long-term suppression that could disrupt host immune function. This allows controlled, temporary intervention in viral replication.
Data Source
AI summary
The invention relates to compounds of Formula (I)and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may inhibit the activity of papain-like protease (PLpro) and may be useful in the treatment of viral infections, in particular viral infections associated with PLpro activity and/or expression such as coronaviruses infections.